|Videos|May 9, 2022
Neratinib for Metastatic HER2+ Breast Cancer and Brain Metastases
Oncologists debate the use of neratinib for metastatic HER2+ breast cancer treatment in the context of the HER2CLIMB clinical trial data on tucatinib.
Advertisement
Episodes in this series
Advertisement
Related to this article
Model data suggest anthracycline-based chemotherapy may cost breast cancer survivors a median of 9.4 life-years through biological age acceleration.
The FDA set a June 25, 2027, PDUFA date for gedatolisib in PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer after endocrine therapy.
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
In HypoMast-IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less grade 3 skin toxicity.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
Anthracycline Chemo May Accelerate Biological Aging in Breast Cancer Survivors
3
Managing Hypoxia, Anemia, and Cardiac Toxicity With Belzutifan Plus Lenvatinib
4
Survival in Childhood and Adolescent Cancers Improves, but Racial Disparities Persist
5